Item 5.02 Departure of Directors or Principal Officers; Election of Directors;


          Appointment of Principal Officers.

On June 5, 2020, following the recommendation of the Compensation Committee of the Board of Directors (the "Board") of Progenics Pharmaceuticals, Inc. (the "Company"), the Board approved the Company's payment of additional cash compensation to David Mims for his service as Interim Chief Financial Officer. As previously disclosed, Mr. Mims was appointed Interim Chief Financial Officer of the Company on March 27, 2020 and continues to serve as Interim Chief Executive Officer of the Company. Pursuant to the Board's approval, Mr. Mims' aggregate cash compensation by the Company will be increased by $10,000 per month for the period of time beginning March 27, 2020 and continuing for so long as he remains Interim Chief Financial Officer of the Company.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses